Upfront Briefing
Lilly led the tape with a $3.8B three-deal vaccine spree — its formal re-entry into infectious disease — while EMA's CHMP cleared a fresh batch of approvals, putting multiple launch clocks on a shorter fuse.
Kardigan's Nasdaq S-1 tests the IPO window; CordenPharma's AmbioPharm bolt-on adds peptide capacity into a tight market. Translation: M&A, regulation, and financing all printed in a single session.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,519.1 |
0.6% |
9.9% |
| Nasdaq 100 |
30,001 |
1.8% |
17.8% |
| Russell 2000 |
2,921.5 |
1.8% |
16.5% |
| Healthcare (XLV) |
148.5 |
(0.9%) |
(4.5%) |
| Biotech (XBI) |
133.4 |
1.3% |
9.4% |
| Nasdaq Biotech (NBI) |
5,913.4 |
0.4% |
3.6% |
| Clinical Trials (BBC) |
43.4 |
1.6% |
12.5% |
|
- Risk-on tape post-Memorial Day: Russell led on small-cap re-rate (1st-ever close above 2,900, +1.8%) with S&P 500 and Nasdaq printing fresh records on softer rate path and renewed U.S.–Iran dialogue.
- Healthcare gave back Friday's defensive bid (XLV -0.9%) as flows rotated into small-cap risk; LLY's $3.8B vaccine M&A and Verve gene-editing data set a constructive idiosyncratic backdrop for biotech large-caps.
- Market data: U.S. close Tue 26-May-2026.
The Big 3
|
1
|
Lilly enters infectious disease with $3.8B three-vaccine M&A spree
|
- Lilly (LLY) announced three separate acquisitions worth up to ~$3.83B combined: Curevo (up to $1.5B, amezosvatein adjuvanted shingles vaccine), LimmaTech Biologics (up to $780M, bacterial pathogens incl. N. gonorrhoeae/chlamydia), and Vaccine Company (up to $1.55B, In Vivo Nanoparticle platform; lead EBV Phase 1-ready candidate).
- Why it matters: Lilly is redeploying GLP-1 cash into prevention assets, opening a fourth franchise leg behind cardiometabolic, oncology, and immunology. The Curevo asset is a direct shot at GSK's Shingrix franchise (~$3.5B sales); the EBV play piggybacks the growing MS/oncology causal evidence base. Bolt-on cadence (Verve, Centessa, Kelonia, Orna, now three vaccines) reinforces LLY's status as 2026's most active biopharma acquirer and tightens the competitive set for any sub-$5B clinical-stage target.
- Source: PR
- More: BioPharma Dive; Bloomberg
|
|
2
|
EMA CHMP backs four novel medicines + 13 label extensions at May meeting
|
- At its 18–21 May plenary, CHMP issued 8 positive opinions (4 novel: Boehringer's Jascayd/nerandomilast in IPF/PPF, Novartis' Vijoice/alpelisib for PROS, plus generics/biosimilar) and recommended 13 indication extensions, including AstraZeneca's camizestrant in ESR1m HR+/HER2- advanced breast cancer.
- Why it matters: CHMP positive opinions typically convert to EC decisions in 2–3 months, pulling EU launch revenue into 2H26. Nerandomilast is the first new IPF agent since pirfenidone/nintedanib — a direct competitive threat to BI's own Ofev franchise extension strategy. Camizestrant's extension de-risks the ESR1m bucket and pressures Lilly's imlunestrant readouts.
- Source: EMA; BioCentury
|
|
3
|
Kardigan files S-1 for Nasdaq IPO behind three cardiovascular programs
|
- Kardigan filed an S-1 to list on Nasdaq, with proceeds earmarked to advance three cardiovascular programs in HFpEF, hypertension, and hypertrophic cardiomyopathy. Lead asset is a Phase 2/3-stage cardiovascular candidate.
- Why it matters: Following BioAge's Q1 print and a year-light biotech IPO calendar, Kardigan is a real-time test of public market receptivity for clinical-stage cardio. Pricing + aftermarket sets the bar for the next wave of crossover-backed names eyeing 2H26 windows; a clean offering accelerates VC mark-up cycles and could unfreeze the back half of the IPO pipeline.
- Source: SEC filing
|
Everything Else that broke
- Apogee (APGE) hosts call today to report Part B 16-week Phase 2 APEX data for zumilokibart in moderate-to-severe atopic dermatitis. — IR
- Foresee posts positive Phase 3 CPP topline for leuprolide. — PR
- Hansa reports positive Idefirix transplant study data. — PR
- Roche launches certified liver disease algorithm panel. — PR
- Junshi says Phase 3 perioperative NSCLC study met endpoints. — PR
- Merck's post-Keytruda NSCLC strategy advances at ASCO. — BioCentury
- MediciNova completes last patient visit in MN-001 trial. — PR
- Jade doses first participant in Phase 1 JADE201 trial. — PR
- Myriad launches Prolaris + AI prostate cancer test. — PR
- Intravacc secures French CIR approval for vaccine R&D. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Eli Lilly announces three vaccine acquisitions worth up to ~$3.83B combined: Curevo (up to $1.5B), LimmaTech Biologics (up to $780M), Vaccine Company (up to $1.55B). — PR; BioCentury
-
CordenPharma acquires AmbioPharm to expand global peptide API capacity (terms undisclosed; adds GLP-1 / next-wave peptide manufacturing scale). — PR
-
Bonito Biosciences and DaltonTx announce AI-driven collaboration on precision oligotherapeutic delivery. — PR
VC / Private Financings
- No new biotech venture financings of note in the last 24 hours.
IPOs / Follow-Ons
- Kardigan files S-1 for Nasdaq IPO behind three cardiovascular programs. — SEC filing
- Nanobiotix closes global offering. — PR
Academic Corner - Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. — Nature Medicine
|
